Comments on: Vedolizumab (Entyvio®) Achieves Superior Rates of Clinical Remission vs. Adalimumab (Humira®) in First Ever Head-to-Head Biologic Clinical Study in Ulcerative Colitis

Comments on: Vedolizumab (Entyvio®) Achieves Superior Rates of Clinical Remission vs. Adalimumab (Humira®) in First Ever Head-to-Head Biologic Clinical Study in Ulcerative Colitis https://www.novumpr.nl/2019/03/09/vedolizumab-entyvio-achieves-superior-rates-of-clinical-remission-vs-adalimumab-humira-in-first-ever-head-to-head-biologic-clinical-study-in-ulcerative-colitis/?utm_source=rss&utm_medium=rss&utm_campaign=vedolizumab-entyvio-achieves-superior-rates-of-clinical-remission-vs-adalimumab-humira-in-first-ever-head-to-head-biologic-clinical-study-in-ulcerative-colitis NovumPR press releases Mon, 11 Mar 2019 06:40:35 +0000 hourly 1 https://wordpress.org/?v=6.8.2